See All News >
Theranos Allegedly Sent Team of Five Lawyers to Wall Street Journal to Squash Story
Biogen (BIIB) Spinning Off Hemophilia Business to Focus On Neurological Disorders
3 Stocks with Moonshot Potential that are Safer Buys than bluebird bio (BLUE)
Amid Hemophilia Spinoff, Biogen (BIIB)’s Head of Strategy Returns to Bain Capital
IMS Health, Quintiles (Q) to Merge to Form $23 Billion Power House
Why a Medivation (MDVN) Takeover Just Got a Little Tougher for Potential Suitors Like AstraZeneca PLC (AZN), Pfizer (PFE) and Sanofi (SNY)
Delaware Employees Nervous Over AstraZeneca PLC (AZN)'s $1 Billion Cost-Cutting Plans
Federal Judge Reopens Gilead (GILD) Case Amid Allegations Former Merck & Co. (MRK) Scientist Lied
Backed by Celgene (CELG) and Novartis AG (NVS), IDEAYA Biosciences Raises $46 Million and Recruits an Arsenal Full of Industry Vets
Pfizer (PFE) Rumored to be Selling Its Hospira Pumps Division, With Smiths Group, Fresenius SE and Pamplona Capital Bidding
Ionis Pharma (IONS), Kastle Forge $95 Million KYNAMRO Deal
Dynavax (DVAX)'s Possible Hep B Win Could Prove a Threat to GlaxoSmithKline (GSK)
Why Sarepta (SRPT) Didn't Start a Big DMD Trial Quicker
Cambridge's BIND Therapeutics (BIND) Files for Chapter 11 and Reviews Strategic Alternatives
MVM Life Science Partners Closes $233 Million Healthcare Fund
Novartis AG (NVS)'s Chief Ethics and Compliance Officer Retires
The Blues Singer Who Created America's Hated Drug-Pricing Model
Eli Lilly (LLY) Warns of Job Cuts at Irish Plant
See All News >